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jects. Mean annual costs were $18,630 (SD$40,365) and $4510
(SD$11,185) among those with and without renal disease
(p < 0.001). Subjects with renal disease had 13.03 (SD11.50)
ofﬁce visits and 0.46 (SD0.85) hospitalizations (average length of
stay of 8.63 days (SD14.60)) per year compared to 6.50 (SD7.31),
0.09 (SD0.31) and 3.63 days (SD10.36) in those without renal
disease (p < 0.001, all measures). Among subjects with renal
disease, 398 (54%), 175 (23%), and 172 (23%) were classiﬁed
with mild, moderate, and severe disease. Annual total health care
costs were $10,888 (SD$21,676), $13,692 (SD$18,114) and
$41,570 (SD$70,502) among these subjects (p < 0.001). A GLM
model adjusting for age, gender, rate of gout ﬂares, use of allopu-
rinol and Charlson comorbidity score indicated that costs were
1.89, 2.17, and 4.91 times greater among subject with mild,
moderate and severe renal impairment compared to those with no
renal disease. Subjectswithmild,moderate, and severe disease had
annual hospitalization rates of 0.25 (SD0.50); 0.58 (SD0.99); and
0.83 (SD1.16) (p < 0.001). CONCLUSION: Health care expen-
ditures and utilization among subjects with incident gout is sub-
stantially higher among those with renal disease, increasing
substantially with severity. Better management may result in
reduction in health care cost and resource utilization.
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OBJECTIVE: There are limited data on the economic impact of
mood disorders among patients with diabetic neuropathy (DN).
This study examines factors associated with health care costs
among elderly DN patients with or without depression/anxiety
(DA). METHODS: Using a retrospective cohort design and
administrative claims data, we assessed the predictors of total
health care costs over a one-year follow-up period for over-age-65
patients with 1+ diagnosis of DN. The index date was deﬁned as
the ﬁrst observed medical claim with a diagnosis for DN in 2005.
Patients with continuous eligibility for 12 months prior to and
following the index date were included. Two cohorts of patients
were constructed for individuals with DA (DN-DA) or without
(DN-only).Multivariate linear regressionwas performed to assess
whether DN-DA patients have higher health care costs than
DN-only patients, controlling for demographic and clinical char-
acteristics (diabetes-related comorbidities and treatment regimen
for diabetes observed within 12 months prior to index date).
RESULTS: We identiﬁed 16,831 DN-only patients, and 1699
DN-DA patients. The DN-only and DN-DA groups were similar
by age (75.6 vs 75.4, p = 0.44), but DN-DA patients were more
likely to be female (56% vs. 47%, p < 0.01). DN-DA patients had
higher prevalence of diabetes-related comorbidities for cardiovas-
cular disease, nephropathy, neuropathy, obesity, and hypoglyce-
mic events than DN-only patients (all p < 0.01). Controlling for
differences in demographic and clinical characteristics, DN-DA
patients had $9785 (p < 0.01) higher total health care costs than
patients with DN-only. Factors associated with increased costs
included insurance type, geographical region, diabetes-related
comorbidities, and insulin therapy. CONCLUSION: These ﬁnd-
ings indicate that the health care costs were signiﬁcantly higher for
DN patients with depression/anxiety relative to those without
these mood disorders.
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OBJECTIVE: Diabetic neuropathy (DN) is one of the most
common complications associated with diabetes. Other diabetes-
related complications include depression, cardiovascular disease,
stroke, renal complications, skin problems, visual impairment,
and amputation. This study assesses the prevalence of other
diabetes-related complications and its marginal contribution on
medical charges among DN patients. METHODS: Commercially
insured patients aged 18–64 with at least 1 claim of DN anytime
between July 2004 and June 2005 (Year 1) enrolled in a large
health plan were selected. A demographically-matched control
cohort of patients with diabetes was constructed via propensity
scoring with a 10:1 ratio to DN cohort. Both DN patients and
controls had 12 months of continuous enrollment in both Year 1
and Year 2 (July 2005-June 2006). The prevalence of other
diabetes-associated complications was compared between DN
patients and controls. Using multivariate regressions, we exam-
ined the marginal contribution of1 other diabetes-related com-
plications on Year 2 medical charges for both cohorts controlling
for comorbidities. We also assessed the impact of DN on medical
charges.RESULTS: Fewer DN patients (11% out of 8655) had no
other diabetes-related complications than controls (24% out of
86,550). Prevalence was statistically higher for all other diabetes-
related complications in the DN group than in the control cohort
with heart disease being the most common in both groups (76%
for DN vs. 68% for controls). Controlling for comorbidities,
patients with 1 other diabetes-related complications had statis-
tically higher pharmacy and total medical charges for both DN
and controls. Charges were also higher for DN patients among
thosewith orwithout other diabetes-related complications.CON-
CLUSION: DN can occur in absence of other diabetes-related
complications. DN and other diabetes-related complications have
signiﬁcant impact on medical charges.
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OBJECTIVE: To identify factors associated with high health care
charges in patients diagnosed with diabetic neuropathy (DN).
METHODS: Data were extracted from a large, commercial
health plan database between July 2004 and June 2006. Patients
aged 18–64 were selected if they had a DN diagnosis (ICD9:
357.2x; 250.6x) between July 2004 and June 2005 (Year 1) and
were continuously enrolled over the study period. High (low)
charges groups were constructed for patients in the top and
bottom decile of annual charges. Comorbidities in Year 1 were
identiﬁed, and total charges in Year 2 (July 2005-June 2006)
were examined. Logistic regression was used to identify factors
associated with high charges. The factors considered were age,
gender, type of health plan, and other comorbidities. RESULTS:
A total of 8655 DN patients (mean age 51 years, 46% female)
were included in the study. Compared to the low charges group,
patients in the high charges group had signiﬁcantly more unique
number of co-morbid medical conditions (16 vs. 10) and higher
charges ($231,898 vs. $20,213) (both p < 0.001). The high
charges group contributed 56% of the total charges of all DN
patients. Factors signiﬁcantly (p < 0.001) contributing to high
charges included dialysis status (OR = 19.2),metastatic cancer
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and acute leukemia (OR = 3.4), end-stage liver disease
(OR = 2.8), renal failure (OR = 2.8), kidney transplant status
(OR = 2.8), severe hematological disorders (OR = 2.4), decubi-
tus ulcer of skin (OR = 1.9), congestive heart failure (OR = 1.9),
pancreatic disease (OR = 1.7), and major depressive/bipolar/
paranoid (OR = 1.7), peripheral vascular disease (OR = 1.6), and
type 1 diabetes (OR = 1.4). Age, gender, and type of insurance
were not signiﬁcantly related to high charges. CONCLUSION:
The most expensive DN patients spent over 50% of the total
charges. The comorbidities of DN patients incurred signiﬁcant
treatment charges. Managing comorbidities is important for
treating patients with DN.
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OBJECTIVE: Type 1 (T1D) and type 2 (T2D) diabetes are
serious and costly medical conditions. Complications related to
diabetes include diabetic neuropathy (DN), heart disease,
kidney disease, visual impairment, depression, and amputation.
Using claims data, we estimated the impact of T1D or any
other diabetes-related complications on health care charges and
utilization among DN patients. METHODS: Individuals who
were 18–64 years old and continuously enrolled in a large US
commercial plan between July 2004 and June 2006 were iden-
tiﬁed. The DN cohort was constructed by selecting patients
with at least 1 DN diagnosis anytime between July 2004 and
June 2005 (Year 1). We compared the prevalence of other
diabetes-related complications by type of diabetes (T1D vs.
T2D). Among DN patients with no or >/=1 other diabetes-
related complications, we used multivariate regressions to
assess the marginal contribution of T1D vs. T2D on Year 2
(July 2005 through June 2006) health care charges and utiliza-
tion. RESULTS: The majority of DN patients (7720 out of
8665) had >/=1 other diabetes-related complications, and T1D
accounted for 42% of the DN cohort. T1D patients had more
co-morbid medical conditions than patients with T2D (7.6 vs.
6.1 among patients with no other diabetes-related complica-
tions; 13.4 vs. 10.3 among those with >/=1 other diabetes-
related complications). The prevalence was higher for all other
diabetes-related complications, except heart disease, among
patients with T1D than patients with T2D. Controlling for
comorbidities, patients with T1D or T2D had similar health
care utilization among DN patients with no other diabetes-
related complications; however, patients with T1D had signiﬁ-
cantly higher total medical charges than patients with T2D
among those with >/=1 other diabetes-related complications.
CONCLUSION: Many DN patients have T1D and other
diabetes-related complications, which can have signiﬁcant
impact on health care charges and utilization.
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OBJECTIVE: We previously developed an incidence-based
Markov model to estimate the lifetime cost of type 2 diabetes
(T2DM) in Colombia. Here, we adapted it to seven other coun-
tries, representing almost 77.9% of Latin America. To estimate
the total direct and indirect lifetime costs of T2DM in Latin
America. METHODS: The model was adapted to each country
using country-speciﬁc epidemiologic rates and cost inputs. Due
to the lack of centralized databases in this region, purchase
power parity conversion factor was used. Costs in 2007 USD
(adjusted using the Consumer Price Index) and outcomes were
modeled over a 32-year time horizon using a 5% discount rate
for both. We calculated the direct, indirect, and total cost/
patient/year, then used epidemiological data to extrapolate to
all persons with T2DM in each country. Costs were summed
for the eight countries, then projected to Latin America, weigh-
ing by population estimates. RESULTS: Total direct costs for
Latin America were $22.8 billion, indirect costs were $46.9
billion, for a total of $69.7 billion for 2007. Colombia had the
lowest total cost/patient/year $847, although Venezuela had
lowest direct costs ($254 versus $288) and Peru had lowest
indirect costs ($547 versus $559); Mexico was highest ($1340/
patient/year); Brazil and Mexico were responsible for 63% of
direct and 62% of indirect costs in Latin America. These costs
differ from those estimated using a prevalence based model
(direct = $10.7, indirect = $54.5, total = $65.2 billion). CON-
CLUSION: This study presents new tools to estimate the cost
of illness for type 2 diabetes in Latin America. However, results
must be considered as rough estimates and validations are
required to verify them.
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OBJECTIVE: Tennessee residents face a heavy economic burden
of diabetes. Costs of hospitalization and treatment were $2.9
billion in 2003, with Tennessee ranking ﬁfth among the 50 states
in the prevalence of diagnosed diabetes. This study explores the
factors inﬂuencing these high inpatient and outpatient hospital
costs for patients with a primary diagnosis of diabetes in Ten-
nessee. We hypothesize that total charges will be most associated
with number or type of comorbidities, and also inﬂuenced by
race/ethnicity, source of admission, and type of insurance.
METHODS: This study utilized inpatient and outpatient ﬁles
from the 2003 Tennessee Hospital Discharge Data. Regression
models of log inpatient and outpatient charges were estimated
for all hospitalizations with a primary diagnosis of diabetes
(ICD-9 code: 250). RESULTS: As predicted, the most signiﬁcant
cost drivers were co-morbidities. A secondary diagnosis of dia-
betic ulcer added nearly $4800 to inpatient charges for diabetics,
and a diagnosis of heart failure contributed an additional $2000.
For outpatients, a secondary diagnosis of ﬂuid balance disorders
added $511 to total charges. Blacks, males, the elderly, and those
insured by managed care plans had signiﬁcantly higher inpatient
charges (all p < 0.01). In contrast, blacks, females, and those
with private insurance had signiﬁcantly higher outpatient charges
(all p < 0.01). CONCLUSION: To design strategies for decreas-
ing the high cost of diabetic treatment, it is critical to understand
the factors that induce increases in cost. The analysis revealed
that of the seven most frequent co-morbidities, ulcers contributed
most to the cost of diabetic hospitalizations. Complications of
diabetic ulcers may have necessitated further or longer treatment,
ultimately increasing charges. Thus, one strategy to reduce exces-
sive costs of treatment is to focus on ulcer prevention among
diabetics.
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